-
Dendreon Pharmaceuticals LLC is a
biotechnology company. Its lead product,
Provenge (known
generically as si****ucel-T), is an
immunotherapy for prostate...
-
Corporation (IRC)
developed this
immunotherapy and
licensed the
technology to
Dendreon,
which obtained FDA clearance. The
current approaches for DC-based vaccination...
-
company had sold its
skincare brands to L'Oréal for $1.3
billion and its
Dendreon biotech unit to
Sanpower for $819.9 million. In June, the
company sold...
- countries. CJ was
recently reported to be in
talks with the US
corporation Dendreon which is in
trials with a
cancer vaccine called Provenge. [citation needed]...
- all
indication of rNAPc2 and
other rNAPc molecules owned by
Dendreon Corporation.
Dendreon was paid an
upfront fee of $4.0
million with an
additional $23...
- Si****ucel-T, sold
under the
brand name Provenge,
developed by
Dendreon Pharmaceuticals, LLC, is a cell-based
cancer immunotherapy for
prostate cancer...
- by 44.2 months,
versus 30.6
months for the control. On
April 14, 2009,
Dendreon Corporation announced that
their Phase III
clinical trial of si****ucel-T...
- no
vaccines able to
prevent cancer in general. On
April 14, 2009, The
Dendreon Corporation announced that
their Phase III
clinical trial of Provenge,...
-
Airlines (#459), and
Expedia (#500).
Alder Biopharmaceuticals (Bot****)
Dendreon –
immunotherapeutics (defunct) Juno
Therapeutics NanoString Technologies...
- a
therapeutic cancer vaccine (TCV) in
development (clinical trial) by
Dendreon (DNDN). It uses the "immunotherapy
platform approach"
first successfully...
